Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies

NCT04020185 is registered in ClinicalTrials.gov with ImmuneSensor Therapeutics Inc. as lead sponsor.

NCT NCT04020185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04020185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Lead sponsor
ImmuneSensor Therapeutics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 23, 2019
Completion date
September 15, 2023
Enrollment
40 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult